Effect of Aromatase Inhibitors on Ultrasonographic Measurements and Static and Dynamic Balance Scores in Breast Cancer

Launched by SULTAN ABDULHAMID HAN TRAINING AND RESEARCH HOSPITAL, ISTANBUL, TURKEY · Dec 14, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how aromatase inhibitors, a type of medication often used to treat breast cancer, affect balance and certain measurements in the legs of women diagnosed with breast cancer. The study aims to understand whether these medications have any impact on the ability to maintain balance and the health of the lower extremities in patients who have undergone treatment for breast cancer.

To participate in this trial, women must be between 40 and 70 years old, postmenopausal, and diagnosed with stage 1 to 3 breast cancer. They should have completed chemotherapy at least six months ago. Participants will be divided into two groups: one group will have been taking aromatase inhibitors for at least a year, while the other group will not have taken these medications at all. Those who join the study will undergo balance tests and ultrasound measurements of their legs. It's important to note that certain health conditions or treatments, such as active chemotherapy or diabetes, may prevent someone from participating. Overall, this study could help us learn more about how these medications affect physical health in breast cancer survivors.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Postmenopausal Woman
• • Between 40-70 ages
• • Stage 1-3 breast cancer
• • Chemotherapy treatment due to breast cancer (Last dosage at least 6 months ago)
• • Using an aromatase inhibitors for at least 1 year for group 1
• • Never using an aromatase inhibitors at all for group 2
• • Volunteers must sign and agree to participate in the study.
• Exclusion Criteria:
• • Stage 4 breast cancer
• • Having active chemotherapy
• • Older age patient (over 70 years old)
• • Using of steroid
• • Presence of diabetes mellitus that lasts longer than 3 years or insulin usage
• • Neuropathic complaints
• • Lack of vitamin B12 and thyroid dysfunction
• • Dn4 (dolour neuropathic 4 question) score of 4 and above
• • History of stroke
• • Presence of polyneuropathy diagnosis
• • Medication due to polyneuropathy diagnosis (gabapentin, pregabalin, duloxetine)
• • Loss of motor function in the lower extremity
• • Use of assistive devices for walking
• • Presence of vestibular disorder
• • Presence of cognitive impairment